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Abstract
Background : Propofol use during sedation for colonoscopy can result in cardiopulmonary complications. Intravenous lidocaine can alleviate visceral pain and decrease propofol requirements during surgery. We tested the hypothesis that i.v. lidocaine reduces propofol requirements during colonoscopy and improves post-colonoscopy recovery. 
Methods: Forty patients undergoing colonoscopy were included in this randomised placebo-controlled study. After titration of propofol to produce unconsciousness, patients were given i.v. lidocaine (1.5 mg kg-1 then 4 mg kg-1 h-1) or the same volume of saline. Sedation was standardised and combined propofol and ketamine. The primary endpoint was propofol requirements. Secondary endpoints were: number of oxygen desaturation episodes, endoscopists' working conditions, discharge time to the recovery room, post-colonoscopy pain, fatigue.
Results: Lidocaine infusion resulted in a significant reduction in propofol requirements: 58 (47) vs 121 (109) mg (P=0.02). Doses of ketamine were similar in the two groups: 19 (2) us 20 (3) mg in the lidocaine and saline groups, respectively. Number of episodes of oxygen desaturation, endoscopists' comfort, and times for discharge to the recovery room were similar in both groups. Post-colonoscopy pain (P<0.01) and fatigue (P=0.03) were significantly lower in the lidocaine group.
Conclusions: Intravenous infusion of lidocaine resulted in a 50% reduction in propofol dose requirements during colonoscopy. Immediate post-colonoscopy pain and fatigue were also improved by lidocaine. 
Clinical trial registration: NCT 02784860.
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Editor's key points
•  Propofol is commonly used for sedation during colonoscopy, but this is associated with haemodynamic and respiratory adverse effects.
•  Propofol is commonly used in combination with an opioid, analgesic adjunct, or both.
•  Intravenous lidocaine, which is known to alleviate visceral pain, reduced propofol requirements by 50% and reduced postprocedural pain and fatigue.

Anaesthesia providers are increasingly involved in providing procedural sedation and analgesia (PSA) for gastrointestinal endoscopy. In Europe, tens of millions of people undergo endoscopic procedures every year.1 In 2010, colonoscopy for colon cancer screening had been performed at least once in more than 50% of Americans during the past 10 yr.2 The most commonly used medications for PSA are midazolam, propofol, and opioid. Each of these drugs, however, causes respiratory depression3 and combining midazolam or propofol with opioid further increases the risk for hypoxemia and apnoea.4,5 A 2006 review of closed malpractice claims in the ASA closed claim database found that respiratory depression secondary to oversedation played a pivotal role in patients' injuries during PSA.6
Nowadays, propofol use for PSA is one of the most popular techniques because of its short onset time and quicker recovery profile.7 Propofol also improves patient satisfaction.7 However, the risk of respiratory and hemodynamic complications when using propofol or midazolam for PSA was reported to be similar (10-14.5%).7,8 Nevertheless, during colonoscopy, propofol sedation results in fewer cardiopulmonary complications than midazolam.8
Different strategies have been tried to reduce the incidence and frequency of complications during PSA. Dexmedetomidine, which possesses anxiolytic and sedative properties without respiratory side-effects, has been assessed in digestive endoscopy.9,10 Unfortunately, dexmedetomidine causes prolonged hypotension and bradycardia. It also results in less patient satisfaction than propofol, which precludes its use as sole sedative medication.10 Another strategy consists of combining propofol with an adjunct medication to reduce the needs for propofol and the incidence of propofol-induced adverse effects. Low doses of ketamine have propofol-sparing effects, and so propofol-ketamine combinations are associated with fewer cardiopulmonary adverse effects than with propofol alone.11-13 I.V. lidocaine is another potentially interesting adjunct to propofol sedation. Benefits of i.v. lidocaine were reported mainly in cases of visceral surgery.14 Indeed, i.v. lidocaine can reduce visceral pain in experimental animal models14-16 and alleviate abdominal pain in patients.17,18 Colonic distension and traction during colonoscopy result in abdominal discomfort and visceral pain potentially amenable to i.v. lidocaine. Furthermore, lidocaine infusion increases the ventilatory response to CO2 in humans.19 We therefore tested the hypothesis that i.v. lidocaine reduces propofol requirements during colonoscopy and improves post-colonoscopy recovery.

METHODS
This study was approved by the Institutional Ethics Committee of Centre Hospitalier Universitaire de Liège (Liège, Belgium, Chairperson: Prof. V. Seutin, No 2016-36) and registered with Clinical Trials (ref: NCT02784860). After obtaining written informed consent, 40 ASA 1-2 patients undergoing colonoscopy under sedation were included in this randomised placebo-controlled double blind study (see Fig. 1 for CONsolidated Standards Of Reporting Trials (CONSORT) trial profile). Exclusion criteria were: age <18 and >70yr, renal failure, liver insufficiency, epilepsy, major cardiac arrhythmia, and allergy to lidocaine.
Study protocol
Intravenous sedation was standardised and performed in all patients by the same anaesthetist (C.F.) unaware of patient allocation group. An i.v. bolus injection of propofol 0.5 mg kg-1 was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. A dose of ketamine 0.3 mg kg-1 was administered i.v. after loss of consciousness. Then, patients were randomly and double blindly assigned to one of two groups using sealed envelopes. Patients were given either an i.v. bolus of lidocaine 1.5 mg kg-1 followed by a continuous infusion of 4 mg kg-1 h-1 or the same volume of saline. This dose of lidocaine given for 30 min does not result in toxic plasma levels.20 Study medications were prepared by an anaesthetist (G.H.) involved neither in patient care nor in collection of the study variables. As the initial bolus of lidocaine can result in side-effects, study medications were infused after loss of consciousness to avoid interference with blinding. During colonoscopy, patients were allowed to recover a level of consciousness to answer simple questions. I.V. boluses of propofol 20-30 mg were given in response to abdominal discomfort expressed by the patient or evidenced by grimaces or haemodynamic changes (increase in HR ≥ 20 beats min-1 or in MAP ≥ 10 mm Hg). If propofol was insufficiently effective, ketamine 10 mg was added. During sedation, all patients breathed spontaneously and received oxygen 4 L min-1 through a nasal catheter.
Measurements
The primary endpoint was propofol requirements. Secondary endpoints were: oxygen desaturation episodes [defined as peripheral capillary oxygen desaturation (SpO2) less than 95% and 90%), time for discharge to the recovery room (time between end of exam and ability for the patient to provide his date of birth), post-colonoscopy pain, and fatigue assessed on a 0-10 cm VAS. Pain scores were recorded on admission to the recovery room, 15 and 30 min later; postoperative fatigue was assessed on admission to the recovery room and 30 min later. Endoscopists were also asked to rate the conditions of the examination on a 0-10 cm VAS. Personnel involved in the assessment of these variables were unaware of patient allocation group.
Statistics
A local pilot study determined propofol requirements during colonoscopy: 442 (143) mg per 30 min. We estimated that a sample size of 18 patients per group would provide an 80% power for detecting a 30% difference in propofol needs between groups at an alpha level of 0.05. A total of 40 patients were finally included.
Data were analysed using GraphPad Software (GraphPad Prism® version 5.0a, La jolla, CA, USA). Data expressed as mean (standard   deviation) and as mean (range) for age were compared using Student's t-test. Categorical variables and gender were compared using χ2 test. 


Endoscopists' working conditions [median (inter-quartile range)] were compared using the Mann-Whitney test. Mixed model analysis of variance (ANOVA) was used to compare postoperative pain score and fatigue. A P-value less than 0.05 was considered as statistically significant.





Subject' characteristics and duration of colonoscopy are presented in Table 1. Subjects from the lidocaine group were significantly older as compared with the saline group (P=0.03). The other characteristics were similar in the two groups.


Lidocaine infusion [188 (34) mg] allowed a significant 50% reduction in propofol consumption (P=0.02; Table 2). A similar dose of ketamine was administered in the two groups (Table 2). The numbers of subjects who experienced oxygen desaturation below 95% (five patients in each group) and below 90% (four us five subjects in the lidocaine and saline groups, respectively) were similar in the two groups. 
The times for readiness to be discharged to the recovery room were 3 (1) min in both groups. The conditions of colonoscopy assessed by the colonoscopists on 0-10 VAS were not different in the two groups [9.0 (1) us 9.7 (1) in the saline and lidocaine, respectively). Pain scores after colonoscopy were significantly lower in the lidocaine group [ANOVA: drug effect (df=1, F=5.3): P=0.023; time effect (df=2, F=5.02): P=0.008; interaction (df=2, F=1.56): P=0.2] (Fig. 2). Postoperative fatigue was also significantly lower in the lidocaine group [ANOVA: drug effect (df=1, F=7.64): P=0.007; time effect (df=1, F=7.98): P=0.006; interaction (df=1, F=0.36): P=0.55] (Fig. 3).

Table 1 Subject characteristic data and duration of colonoscopy. Data are mean (range), mean (standard deviation), or number. *significantly different (P<0.05)
	Saline	Lidocaine
Age (yr)	53 (25-65)	59 (41-69)*
Gender (M/F)	8/12	8/12
Weight (kg)	78 (15)	72 (16)
Height (cm)	168 (9)	166 (9)
BMI (kg m-2)	27.4 (4.6)	25.7 (3)
ASA physical status (1/2/3)	8/12/0	6/13/1
Duration of colonoscopy (min)	21(5)	25.7 (3)

Table 2 Propofol, ketamine, and lidocaine consumption. Data are mean (standard deviation). *significantly different (P=0.02), **significantly different (P=0.01)
	Saline	Lidocaine
 Propofol: total dose (mg)	200 (109)	128 (53)**
 Propofol: induction of sedation (mg)	79 (16)	71 (14)
 Propofol: during infusion of study medications (mg)	121 (109)	58 (47)*
 Ketamine (mg)	20(2)	19(3)




This study demonstrates that adding i.v. lidocaine to propofol-ketamine PSA results in a 50% reduction in propofol needs for colonoscopy without affecting endoscopists' working conditions. Intravenous lidocaine also improves post-colonoscopy pain and fatigue.
Discomfort associated to colonoscopy results mainly from visceral nociception secondary to colonic distension and tractions. Yet, experimental studies demonstrate i.v. lidocaine is efficient in alleviating visceral pain.15,16 Accordingly, during visceral surgery, i.v. lidocaine allows for a 30-40% reduction in requirements of intraoperative volatile anaesthetics.18,21 I.V. lidocaine decreases also intraoperative propofol requirements during surgery under total i.v. anaesthesia.20,22 These sparing effects are only observed during surgical stimulation, which suggests a property mediated by an antinociceptive action.20,22,23 We therefore extend these observations to propofol PSA used to relieve visceral nociception during digestive endoscopy. We do not believe that the significant age difference between the two groups explains the propofol-sparing effect of lidocaine. Indeed, if we discard the one patient aged 25 yr in the saline group and the two patients aged 69 yr in the lidocaine group, no significant age difference persists, whereas propofol requirement in the lidocaine group still remains significantly less [lidocaine=127 (55) mg vs saline=195 (105) mg, P=0.012]. It should be noted that this decrease in propofol administration was not at the expense of working conditions as endoscopists' satisfaction was similar in both groups. Doses of ketamine were similar in both groups. Indeed ketamine was administered per-protocol as a dose per kilo, and therefore not titrated, at the beginning of the PSA. Thereafter, additional boluses of ketamine were rarely needed in both groups.
Fig 2. Pain score after colonoscopy. Data are mean (SD). Pain was measured on a 0-10 VAS at arrival in the recovery room (KR), 15 and 30 min later. Pain scores in the lidocaine group (white bars) were significantly lower than in the saline group (black bars) (analysis of variance: P=0.02).


Fig 3. Postoperative fatigue after colonoscopy. Data are mean (SD). Fatigue was assessed on a 0-10 VAS at arrival in the recovery room (RR), and 30 min later. Fatigue in the lidocaine group (white bars) was significantly lower than in the saline group (black bars) (analysis of variance: P=0.007).

Postoperative pain after colorectal surgery is less in the case of perioperative administration of i.v. lidocaine.14
Abdominal discomfort is particularly improved by i.v. lidocaine.18 We report significantly less pain in the lidocaine group. This analgesic effect is weak and probably not clinically relevant. However, pain scores were low in the control group. This is secondary in part to ketamine administration.12 In the absence of ketamine, pain would have probably been more elevated and the analgesic effect of i.v. lidocaine could have been more relevant as reported by others after endoscopic submucosal dissection for gastric neoplasm.24
Fatigue after colonoscopy was improved in the lidocaine group. Similarly, i.v. lidocaine is reported to reduce postoperative fatigue and improve quality of recovery after surgery.18,25 This reduction in post-procedural fatigue might be secondary to the propofol-sparing effect.
Hypoxia and apnoea secondary to respiratory depression and airway obstruction are the most frequent cardiopulmonary complications of PSA for endoscopy.26 One of the aims to administer an adjunct to propofol is to reduce its needs and consequently the incidence of its adverse effects. Accordingly ketamine in combination with propofol is associated with less respiratory depression and fewer adverse respiratory events as compared with propofol alone.12,13 Despite a significant propofol-sparing effect and the potentially increased ventilatory response to CO2 produced by lidocaine,19 we did not observe any reduction in the number of patients with oxygen desaturation in the lidocaine group. The percentage of patients who experienced episodes of oxygen desaturation could appear elevated (25%). These numbers are certainly greater than those reported in large databases.27 However, the latter frequently underestimate the actual frequency of acute complications because of missing data and underreporting. Nevertheless, our results are in the range of those reported by others during sedation when hypoxaemia is prospectively searched for.28 We decided to administer only 4 L min-1 of oxygen through a nasal catheter and not a greater flow via a facemask to make SpO2 more sensitive to potential respiratory depression and airway obstruction, and to detect possibly between-groups differences more easily. Our patient management may have contributed, therefore, to the high number of oxygen desaturation. One limitation of our study was that we did not measure the duration of the episodes of oxygen desaturation, which could have allowed us to detect beneficial effects of lidocaine.
Our study has some limitations. It was powered and designed to detect a significant propofol-sparing effect, but not to ascertain the potential benefits of this reduction on propofol-induced adverse events, which can be significant with this procedure.29 As mentioned earlier, recording of the duration of oxygen desaturation (maybe without supplemental oxygen) might help detect differences in the magnitude of respiratory depression. Finally, the doses of ketamine we administered seem to have precluded demonstration of benefits potentially associated with the propofol-sparing effects. Repeating the study without ketamine, which some anaesthetists might be reluctant to use for outpatient procedures, should be useful to ascertain potential post-procedural benefits of lidocaine.
In conclusion, i.v. lidocaine allows for a 50% reduction in propofol needs when combined with ketamine during PSA for colonoscopy, without impacting working conditions for the endoscopists. Lidocaine also improves post-colonoscopy pain and fatigue. Our protocol and the power of the study calculated to detect a difference in propofol need did not allow us to detect reduction in the incidence of oxygen desaturation despite this propofol-sparing effect.
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